Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088530 · ClinicalTrials.gov registry record · Phase 3
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
A Phase 3 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
NCT00088530: Completed Phase 3 study, sponsored by CTI BioPharma.
NCT00088530 is a Phase 3 study that has completed, run by CTI BioPharma. The registered enrollment target is 140 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088530, a Phase 3 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
Study Summary
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quinoid chromophore).
Primary Outcome
Proportion of patients with a best response of complete response (CR) or Complete Response unconfirmed (CRu) in the End Of Treatment (EOT) or End Of Study (EOS) analyses by independent assessment in the Intent-to-treat (ITT) population through the End of Treatment (EOT)
Interventions
- DRUG pixantrone, cyclophosphamide, vincristine, rituximab, prednisone
- DRUG Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2004-07 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
What the finished NCT00088530 record still lists
NCT00088530 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which pixantrone, cyclophosphamide, vincristine, rituximab, prednisone is the first listed.
NCT00088530 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00088530 about?
NCT00088530 is a clinical study titled "BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)". BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quin...
What is the current status of trial NCT00088530?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2004-07. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00088530?
The interventions under investigation include: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone (DRUG), Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab (DRUG).
Who is sponsoring clinical trial NCT00088530?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00088530's enrollment target sits among peer trials
140 1565th of 2000 higher than 424 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia